AstraZeneca’s COVID-19 vaccine trial in the United States is expected to resume as early as this week after the US Food and Drug Administration completed its review of a serious illness in a study participant, sources told Reuters on Tuesday.
AstraZeneca’s large, late-stage US trial has been on hold since September 6, after a participant in the company’s UK trial fell ill with what was suspected to be a rare spinal inflammatory disorder called transverse myelitis.